title: [Bioavailability of sotalol in short bowel syndrome].
abstract: BACKGROUND
  The individual bioavailability of enterally administered drugs is usually uncertain in case of reduced bowel length. Routine measurements of plasma concentrations are available only for a small number of drugs. The daily dose recommended by the manufacturers may result in subtherapeutic plasma concentrations when given to such patients.
  
  
  METHODS
  In 2 patients with hemodynamically relevant atrial fibrillation and reduced gut length application of increasing sotalol doses was initiated. For the assessment of the individual bioavailability plasma concentrations were measured via HPLC immediately before and 2 hours after enteral application of sotalol. Judging by clinical criteria both patients were treated successfully. Even in the patient with severe short bowel syndrome (stomach, duodenum and 50 cm jejunal remnant) doubling of the daily dose led to a substantial increase in plasma concentrations.
  
  
  CONCLUSIONS
  Effective enteral medication with sotalol in patients with short residual bowel is possible. Normal plasma concentrations can be achieved by administering doses according to the manufacturers' instructions. In case of severe short bowel syndrome, the measurements of plasma concentrations may be beneficial in supervising dose-adjustment.
authors.affiliation: Klinik für Anästhesiologie und Intensivmedizin, Universitätskliniken des Saarlandes, Homburg/Saar. aimsil@med-rz.uni-sb.de
authors.forename: M
authors.initials: M
authors.lastname: Silomon
authors.forename: F
authors.initials: F
authors.lastname: Bach
authors.forename: S
authors.initials: S
authors.lastname: Juckenhöfel
authors.forename: T
authors.initials: T
authors.lastname: Claus
authors.forename: G
authors.initials: G
authors.lastname: Molter
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008875:Middle Aged; D012778:Short Bowel Syndrome / Q000097:blood / Q000150:complications*; D013015:Sotalol / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013610:Tachycardia / Q000097:blood / Q000150:complications* / Q000188:drug therapy*
chemical_list: D000889:Anti-Arrhythmia Agents; D013015:Sotalol
vernacular_title: Bioverfügbarkeit von Sotalol bei verkürzter gastrointestinaler Passage.